Cargando…

Oligonucleotide correction of an intronic TIMMDC1 variant in cells of patients with severe neurodegenerative disorder

TIMMDC1 encodes the Translocase of Inner Mitochondrial Membrane Domain-Containing protein 1 (TIMMDC1) subunit of complex I of the electron transport chain responsible for ATP production. We studied a consanguineous family with two affected children, now deceased, who presented with failure to thrive...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumar, Raman, Corbett, Mark A., Smith, Nicholas J. C., Hock, Daniella H., Kikhtyak, Zoya, Semcesen, Liana N., Morimoto, Atsushi, Lee, Sangmoon, Stroud, David A., Gleeson, Joseph G., Haan, Eric A., Gecz, Jozef
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799713/
https://www.ncbi.nlm.nih.gov/pubmed/35091571
http://dx.doi.org/10.1038/s41525-021-00277-7
_version_ 1784642120620965888
author Kumar, Raman
Corbett, Mark A.
Smith, Nicholas J. C.
Hock, Daniella H.
Kikhtyak, Zoya
Semcesen, Liana N.
Morimoto, Atsushi
Lee, Sangmoon
Stroud, David A.
Gleeson, Joseph G.
Haan, Eric A.
Gecz, Jozef
author_facet Kumar, Raman
Corbett, Mark A.
Smith, Nicholas J. C.
Hock, Daniella H.
Kikhtyak, Zoya
Semcesen, Liana N.
Morimoto, Atsushi
Lee, Sangmoon
Stroud, David A.
Gleeson, Joseph G.
Haan, Eric A.
Gecz, Jozef
author_sort Kumar, Raman
collection PubMed
description TIMMDC1 encodes the Translocase of Inner Mitochondrial Membrane Domain-Containing protein 1 (TIMMDC1) subunit of complex I of the electron transport chain responsible for ATP production. We studied a consanguineous family with two affected children, now deceased, who presented with failure to thrive in the early postnatal period, poor feeding, hypotonia, peripheral neuropathy and drug-resistant epilepsy. Genome sequencing data revealed a known, deep intronic pathogenic variant TIMMDC1 c.597-1340A>G, also present in gnomAD (~1/5000 frequency), that enhances aberrant splicing. Using RNA and protein analysis we show almost complete loss of TIMMDC1 protein and compromised mitochondrial complex I function. We have designed and applied two different splice-switching antisense oligonucleotides (SSO) to restore normal TIMMDC1 mRNA processing and protein levels in patients’ cells. Quantitative proteomics and real-time metabolic analysis of mitochondrial function on patient fibroblasts treated with SSOs showed restoration of complex I subunit abundance and function. SSO-mediated therapy of this inevitably fatal TIMMDC1 neurologic disorder is an attractive possibility.
format Online
Article
Text
id pubmed-8799713
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-87997132022-02-07 Oligonucleotide correction of an intronic TIMMDC1 variant in cells of patients with severe neurodegenerative disorder Kumar, Raman Corbett, Mark A. Smith, Nicholas J. C. Hock, Daniella H. Kikhtyak, Zoya Semcesen, Liana N. Morimoto, Atsushi Lee, Sangmoon Stroud, David A. Gleeson, Joseph G. Haan, Eric A. Gecz, Jozef NPJ Genom Med Article TIMMDC1 encodes the Translocase of Inner Mitochondrial Membrane Domain-Containing protein 1 (TIMMDC1) subunit of complex I of the electron transport chain responsible for ATP production. We studied a consanguineous family with two affected children, now deceased, who presented with failure to thrive in the early postnatal period, poor feeding, hypotonia, peripheral neuropathy and drug-resistant epilepsy. Genome sequencing data revealed a known, deep intronic pathogenic variant TIMMDC1 c.597-1340A>G, also present in gnomAD (~1/5000 frequency), that enhances aberrant splicing. Using RNA and protein analysis we show almost complete loss of TIMMDC1 protein and compromised mitochondrial complex I function. We have designed and applied two different splice-switching antisense oligonucleotides (SSO) to restore normal TIMMDC1 mRNA processing and protein levels in patients’ cells. Quantitative proteomics and real-time metabolic analysis of mitochondrial function on patient fibroblasts treated with SSOs showed restoration of complex I subunit abundance and function. SSO-mediated therapy of this inevitably fatal TIMMDC1 neurologic disorder is an attractive possibility. Nature Publishing Group UK 2022-01-28 /pmc/articles/PMC8799713/ /pubmed/35091571 http://dx.doi.org/10.1038/s41525-021-00277-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Kumar, Raman
Corbett, Mark A.
Smith, Nicholas J. C.
Hock, Daniella H.
Kikhtyak, Zoya
Semcesen, Liana N.
Morimoto, Atsushi
Lee, Sangmoon
Stroud, David A.
Gleeson, Joseph G.
Haan, Eric A.
Gecz, Jozef
Oligonucleotide correction of an intronic TIMMDC1 variant in cells of patients with severe neurodegenerative disorder
title Oligonucleotide correction of an intronic TIMMDC1 variant in cells of patients with severe neurodegenerative disorder
title_full Oligonucleotide correction of an intronic TIMMDC1 variant in cells of patients with severe neurodegenerative disorder
title_fullStr Oligonucleotide correction of an intronic TIMMDC1 variant in cells of patients with severe neurodegenerative disorder
title_full_unstemmed Oligonucleotide correction of an intronic TIMMDC1 variant in cells of patients with severe neurodegenerative disorder
title_short Oligonucleotide correction of an intronic TIMMDC1 variant in cells of patients with severe neurodegenerative disorder
title_sort oligonucleotide correction of an intronic timmdc1 variant in cells of patients with severe neurodegenerative disorder
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799713/
https://www.ncbi.nlm.nih.gov/pubmed/35091571
http://dx.doi.org/10.1038/s41525-021-00277-7
work_keys_str_mv AT kumarraman oligonucleotidecorrectionofanintronictimmdc1variantincellsofpatientswithsevereneurodegenerativedisorder
AT corbettmarka oligonucleotidecorrectionofanintronictimmdc1variantincellsofpatientswithsevereneurodegenerativedisorder
AT smithnicholasjc oligonucleotidecorrectionofanintronictimmdc1variantincellsofpatientswithsevereneurodegenerativedisorder
AT hockdaniellah oligonucleotidecorrectionofanintronictimmdc1variantincellsofpatientswithsevereneurodegenerativedisorder
AT kikhtyakzoya oligonucleotidecorrectionofanintronictimmdc1variantincellsofpatientswithsevereneurodegenerativedisorder
AT semcesenlianan oligonucleotidecorrectionofanintronictimmdc1variantincellsofpatientswithsevereneurodegenerativedisorder
AT morimotoatsushi oligonucleotidecorrectionofanintronictimmdc1variantincellsofpatientswithsevereneurodegenerativedisorder
AT leesangmoon oligonucleotidecorrectionofanintronictimmdc1variantincellsofpatientswithsevereneurodegenerativedisorder
AT strouddavida oligonucleotidecorrectionofanintronictimmdc1variantincellsofpatientswithsevereneurodegenerativedisorder
AT gleesonjosephg oligonucleotidecorrectionofanintronictimmdc1variantincellsofpatientswithsevereneurodegenerativedisorder
AT haanerica oligonucleotidecorrectionofanintronictimmdc1variantincellsofpatientswithsevereneurodegenerativedisorder
AT geczjozef oligonucleotidecorrectionofanintronictimmdc1variantincellsofpatientswithsevereneurodegenerativedisorder